These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 34937139)
1. Consensus guidelines for the diagnosis and management of invasive fungal disease due to moulds other than Aspergillus in the haematology/oncology setting, 2021. Bupha-Intr O; Butters C; Reynolds G; Kennedy K; Meyer W; Patil S; Bryant P; Morrissey CO; Intern Med J; 2021 Nov; 51 Suppl 7():177-219. PubMed ID: 34937139 [TBL] [Abstract][Full Text] [Related]
2. Rare mould infections caused by Mucorales, Lomentospora prolificans and Fusarium, in San Diego, CA: the role of antifungal combination therapy. Jenks JD; Reed SL; Seidel D; Koehler P; Cornely OA; Mehta SR; Hoenigl M Int J Antimicrob Agents; 2018 Nov; 52(5):706-712. PubMed ID: 30099056 [TBL] [Abstract][Full Text] [Related]
3. Changes in the epidemiological landscape of invasive mould infections and disease. Lass-Flörl C; Cuenca-Estrella M J Antimicrob Chemother; 2017 Mar; 72(suppl_1):i5-i11. PubMed ID: 28355462 [TBL] [Abstract][Full Text] [Related]
4. Non-Aspergillus Hyaline Molds: Emerging Causes of Sino-Pulmonary Fungal Infections and Other Invasive Mycoses. Jacobs SE; Wengenack NL; Walsh TJ Semin Respir Crit Care Med; 2020 Feb; 41(1):115-130. PubMed ID: 32000288 [TBL] [Abstract][Full Text] [Related]
5. Diagnosis of invasive fungal diseases in haematology and oncology: 2018 update of the recommendations of the infectious diseases working party of the German society for hematology and medical oncology (AGIHO). Ruhnke M; Behre G; Buchheidt D; Christopeit M; Hamprecht A; Heinz W; Heussel CP; Horger M; Kurzai O; Karthaus M; Löffler J; Maschmeyer G; Penack O; Rieger C; Rickerts V; Ritter J; Schmidt-Hieber M; Schuelper N; Schwartz S; Ullmann A; Vehreschild JJ; von Lilienfeld-Toal M; Weber T; Wolf HH Mycoses; 2018 Nov; 61(11):796-813. PubMed ID: 30098069 [TBL] [Abstract][Full Text] [Related]
6. Antifungal activity of compounds targeting the Hsp90-calcineurin pathway against various mould species. Lamoth F; Alexander BD; Juvvadi PR; Steinbach WJ J Antimicrob Chemother; 2015 May; 70(5):1408-11. PubMed ID: 25558076 [TBL] [Abstract][Full Text] [Related]
8. Introduction to the updated Australasian consensus guidelines for the management of invasive fungal disease and use of antifungal agents in the haematology/oncology setting, 2021. Chang CC; Blyth CC; Chen SC; Khanina A; Morrissey CO; Roberts JA; Thursky KA; Worth LJ; Slavin MA; Intern Med J; 2021 Nov; 51 Suppl 7():3-17. PubMed ID: 34937135 [TBL] [Abstract][Full Text] [Related]
9. Emergence of the Molds Other than Aspergillus in Immunocompromised Patients. Arif S; Perfect JR Clin Chest Med; 2017 Sep; 38(3):555-573. PubMed ID: 28797495 [TBL] [Abstract][Full Text] [Related]
10. The current treatment landscape: other fungal diseases (cryptococcosis, fusariosis and mucormycosis). Lortholary O; Fernández-Ruiz M; Perfect JR J Antimicrob Chemother; 2016 Nov; 71(suppl 2):ii31-ii36. PubMed ID: 27880667 [TBL] [Abstract][Full Text] [Related]
14. Antifungal susceptibilities of non-Aspergillus filamentous fungi causing invasive infection in Australia: support for current antifungal guideline recommendations. Halliday CL; Chen SC; Kidd SE; van Hal S; Chapman B; Heath CH; Lee A; Kennedy KJ; Daveson K; Sorrell TC; Morrissey CO; Marriott DJ; Slavin MA Int J Antimicrob Agents; 2016 Oct; 48(4):453-8. PubMed ID: 27562696 [TBL] [Abstract][Full Text] [Related]
15. Consensus guidelines for the treatment of invasive mould infections in haematological malignancy and haemopoietic stem cell transplantation, 2014. Blyth CC; Gilroy NM; Guy SD; Chambers ST; Cheong EY; Gottlieb T; McGuinness SL; Thursky KA Intern Med J; 2014 Dec; 44(12b):1333-49. PubMed ID: 25482744 [TBL] [Abstract][Full Text] [Related]
16. Prognostic factors in 264 adults with invasive Scedosporium spp. and Lomentospora prolificans infection reported in the literature and FungiScope Seidel D; Meißner A; Lackner M; Piepenbrock E; Salmanton-García J; Stecher M; Mellinghoff S; Hamprecht A; Durán Graeff L; Köhler P; Cheng MP; Denis J; Chedotal I; Chander J; Pakstis DL; Los-Arcos I; Slavin M; Montagna MT; Caggiano G; Mares M; Trauth J; Aurbach U; Vehreschild MJGT; Vehreschild JJ; Duarte RF; Herbrecht R; Wisplinghoff H; Cornely OA Crit Rev Microbiol; 2019 Feb; 45(1):1-21. PubMed ID: 30628529 [TBL] [Abstract][Full Text] [Related]
17. Antifungal susceptibility of clinical mould isolates in New Zealand, 2001-2019. Morris AJ; McKinney WP; Rogers K; Freeman JT; Roberts SA Pathology; 2021 Aug; 53(5):639-644. PubMed ID: 33518383 [TBL] [Abstract][Full Text] [Related]
18. Practical issues related to non-Aspergillus invasive mold infections. Nucci M; Nouér SA Mol Aspects Med; 2023 Dec; 94():101230. PubMed ID: 38011770 [TBL] [Abstract][Full Text] [Related]
19. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. Moen MD; Lyseng-Williamson KA; Scott LJ Drugs; 2009; 69(3):361-92. PubMed ID: 19275278 [TBL] [Abstract][Full Text] [Related]
20. Epidemiology of invasive respiratory disease caused by emerging non-Aspergillus molds in lung transplant recipients. Peghin M; Monforte V; Martin-Gomez MT; Ruiz-Camps I; Berastegui C; Saez B; Riera J; Solé J; Gavaldá J; Roman A Transpl Infect Dis; 2016 Feb; 18(1):70-8. PubMed ID: 26678668 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]